This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

AtriCure Update On DEEP AF Feasibility Trial - Call Transcript

AtriCure ( ATRC)

Update on DEEP AF Feasibility Trial

November 17, 2011 9:00 a.m. ET


David Drachman - President and CEO

Julie Piton - VP, Finance and CFO


Vivian Cervantes - Kaufman Brothers

Matt Dolan - ROTH Capital Partners

Jan Wald - Morgan Keegan

Kevin Kotler - Broadfin Capital



Good morning and welcome to AtriCure’s call to provide an update on its DEEP AF feasibility trial. [Operator instructions.] I would now like to turn the call over to Mr. David Drachman, president and chief executive officer of AtriCure. Mr. Drachman, please proceed.

David Drachman

Good morning and welcome to AtriCure’s call to provide and update on its DEEP AF feasibility trial. My name is David Drachman, and I will be your coordinator for the call today. With me on the call today is Julie Piton, vice president of finance and administration and chief financial officer. At this time, I would like to turn the call over to Julie for a few introductory comments.

Juli e Piton

Thank you Dave, and good morning everyone. Before we begin today, let me remind you that the company’s remarks may include forward looking statements. These statements include, but are not limited to those that address activity, events, or developments that AtriCure expects, believes, or anticipates will or may occur in the future, such as revenue and earnings estimates, other predictions of financial performance, launches of new products, and market acceptance of new products.

Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond AtriCure’s control, including, but not limited to, the rate and degree of market acceptance of AtriCure’s products, governmental approvals and other risks and uncertainties described from time to time in AtriCure’s SEC filings.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 16,877.21 +87.02 0.52%
S&P 500 1,990.23 +10.31 0.52%
NASDAQ 4,778.6240 +30.2630 0.64%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs